PRKDC and colorectal adenocarcinoma: In the Muzny's colorectal adenocarcinoma cohort [20, 21, 22] and the Vesteinn's gastric adenocarcinoma cohort [20, 21, 22], the TMB of PRKDC mut+ samples is significantly higher than in the PRKDC mut− samples only in the MSS/MSS‐L subtypes (median nonsynonymous mutations 3209 vs. 69.50, P < 0.0001 for colorectal adenocarcinoma, 234 vs. 87, P < 0.01 for gastric adenocarcinoma).